biotech · Fibrostenotic Crohn’s disease · liver cirrhosis · AGMB
Agomab Therapeutics NV
Agomab Therapeutics NV clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Tel Aviv, USA
- Founded
- 2011
- Employees
- 20
- Programs
- 6
- Drugs
- 2
- Patents
- 4
Agomab Therapeutics NV projects
6 ClinicalTrials.gov programs sponsored by Agomab Therapeutics NV.
Agomab Therapeutics NV has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
AGMB-129
Agomab Therapeutics NV
Fibrostenotic Crohn's Disease
2 trials -
AGMB-129
Agomab Therapeutics NV
Healthy Volunteers
2 trials -
AGMB-447
Agomab Therapeutics NV
IPF
1 trial -
AGMB101-01-CL-102
Agomab Therapeutics NV
liver cirrhosis
1 trial -
AGMB129-01-CL-109
Agomab Therapeutics NV
Fibrostenotic Crohn’s disease
1 trial -
ORG-129
Agomab Therapeutics NV
Healthy Volunteers
1 trial
Frequently asked questions
How many clinical projects does Agomab Therapeutics NV have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.